Ignite Creation Date:
2025-12-25 @ 5:12 AM
Ignite Modification Date:
2026-07-21 @ 4:01 AM
Study NCT ID:
NCT01750827
Status:
COMPLETED
Last Update Posted:
2012-12-17
First Post:
2012-12-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Assess the Effect of SB 659032 on Platelet Function
Sponsor:
GlaxoSmithKline
Organization:
Study Overview
Official Title:
A Single Dose Study to Assess the Effect of Non-Bioenhanced, Non-Enteric Coated, Freebase SB-659032 on Platelet Function in Healthy Adult Subjects
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This will be an open-label, single dose, single period study. Approximately 14 subjects will receive one dose of 250 mg of non-enteric coated SB-659032 following a low-fat breakfast. This study will evaluate whether SB-659032 has an effect on platelet function as determined by platelet aggregation tests using the agonists ADP and collagen. Blood samples for PK analysis and measurement of Lp-PLA2 activity will also be collected
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: